Global Availability of Varian Halcyon Treatments Expands with First Cancer Patient Treated in Australia | Varian

Global Availability of Varian Halcyon Treatments Expands with First Cancer Patient Treated in Australia

PALO ALTO, Calif. — November 1, 2017 — Representing the latest step in Varian Medical Systems’ (NYSE: VAR) efforts to expand the availability of high quality cancer care globally, the company announced a 71-year-old male with prostate cancer became the first patient in Australia to be treated on the Halcyon system at Radiation Oncology Centres (ROC) in Toowoomba by Brisbane-based Icon Group. Halcyon simplifies and enhances virtually every aspect of image-guided volumetric intensity modulated radiotherapy (IMRT), and is well suited to handle the majority of cancer patients, offering advanced treatments for lung, esophagus, brain, head & neck, and many other forms of cancer.

In addition to delivering high-quality cancer treatments, Halcyon was built with a human-centered user-friendly design that makes this advanced cancer treatment system more comfortable for the patient while delivering ease-of-use for healthcare providers, accelerated installation timeframes, expedited commissioning, simplified training, and automated treatment.

 “We are excited to have begun delivering treatments on the Halcyon system and expanding the availability of advanced cancer care in Australia,” said Mark Middleton, CEO, Icon Group. “Halcyon was extremely efficient and easy to use. After just one day of training with the Varian specialist, the team felt confident using the machine. The 'follow the blue light system' works well and makes it easy for new users to learn. With so much automation involved in the planning, image acquisition and treatment, it is easy to get used to, and the innovative design makes it extremely streamlined and efficient. We believe Halcyon will be of great benefit to a very busy department at ROC.” 

“Icon was one of the very first cancer care groups to order the Halcyon system and we are proud that this technology is now delivering treatments in Australia so soon after it was announced,” said Kolleen Kennedy, president of Varian's Oncology Systems business. “The treatments beginning at ROC are another important step in our vision of creating a world without fear of cancer.”

For more information on Halcyon, visit

About Varian Medical Systems
Varian Medical Systems focuses energy on saving lives and is the world's leading manufacturer of medical devices and software for treating and managing cancer. Headquartered in Palo Alto, California, Varian employs approximately 6,600 people around the world. For more information, visit and follow @VarianMedSys on Twitter.